Upstream Bio Inc.: Piper Sandler Reaffirms Overweight Rating Ahead of Important Study Data with 326% Price Potential

Upstream Bio Inc. (UPB) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The only drug currently in clinical development is Verekitug, a monoclonal antibody that blocks the TSLP receptor. Verekitug aims to suppress the inflammatory response involved in various severe respiratory diseases. The initial focus is on the treatment of severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company believes that Verekitug, due to its...